Regeneron Pharmaceuticals (REGN) Long-Term Debt Issuances (2009 - 2011)

Regeneron Pharmaceuticals' (REGN) quarterly Long-Term Debt Issuances came in at $391.1 million in Q4 2011, up 722.62% quarter-over-quarter from $47.5 million in Q1 2010.

Regeneron Pharmaceuticals (REGN) Long-Term Debt Issuances (2009 - 2011) Analysis & Trends

Regeneron Pharmaceuticals' Long-Term Debt Issuances history runs 3 years deep, the most recent figure standing at $391.1 million for Q4 2011.

  • On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $391.1 million in Q4 2011; TTM through Dec 2021 was $391.1 million, a 0.0% change from a year earlier, with the FY2020 full-year figure at $2.0 billion, changed N/A from the prior year.
  • Long-Term Debt Issuances advanced to $391.1 million in Q4 2011 per REGN's latest filing, from $47.5 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $391.1 million in Q4 2011 and bottomed at $18.5 million in Q4 2009.
  • The 3-year median for Long-Term Debt Issuances is $47.5 million (2010), against an average of $152.4 million.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2011 391.11 Mn
Dec 31, 2011 391.11 Mn
Mar 31, 2010 47.54 Mn
Mar 31, 2010 47.54 Mn
Dec 31, 2009 18.46 Mn
Dec 31, 2009 18.46 Mn